Stimulation of the AT2 receptor with small-molecule agonists offers therapeutic potential for tissue protection and regeneration in cardiovascular and neuronal diseases.
The renin-angiotensin system (RAS) plays an important role in the initiation and progression of tissue injuries in the cardiovascular and nervous systems. The detrimental actions of the AT1 receptor (AT1R) in hypertension and vascular injury, myocardial infarction and brain ischemia are well established. In the past twenty years, protective actions of the RAS, not only in the cardiovascular, but also in the nervous system, have been demonstrated. The so-called protective arm of the RAS includes AT2-receptors and Mas receptors (AT2R and MasR) and is characterized by effects different from and often opposing those of the AT1R. These include anti-inflammation, anti-fibrosis, anti-apoptosis and neuroregeneration that can counterbalance pathological processes and enable recovery from disease. The recent development of novel, small-molecule AT2R agonists offers a therapeutic potential in humans with a variety of clinical indications.
Namsolleck et al. (Fri,) conducted a review in Cardiovascular and neuronal tissue injury. AT2 receptor agonists was evaluated. Stimulation of the AT2 receptor with small-molecule agonists offers therapeutic potential for tissue protection and regeneration in cardiovascular and neuronal diseases.